James Stauner

James P. Stauner is a long-time healthcare operating executive and investor who spent much of his career at RoundTable Healthcare Partners, the Lake Forest, Illinois operating-oriented private equity firm that invests exclusively in the healthcare industry. Public business-leader records list him as a Senior Advisor to RoundTable Healthcare Management (cited circa 2019–2021) and elsewhere as an Operating Partner/Partner; his LinkedIn profile now lists him as retired from the firm. His firm email ([hidden]) and the RoundTable main line (847-739-3200) remain the verified contact points.

Before his RoundTable advisory work, Stauner built a senior operating career in healthcare products and distribution. According to MarketScreener's executive record, he was President of the Manufacturing Business Groups at Cardinal Health, Inc. (1999–2005), and earlier held roles at Baxter Healthcare Corp. (1985–1996), Allegiance Corp., and American Hospital Supply Corp. (1977–1984). This operating background — in medical devices, manufacturing, M&A, and corporate development — is consistent with RoundTable's "operators-as-investors" model.

In the investor and board capacity, Stauner has served on the boards of several RoundTable-related and medical-device companies. He was Chairman of Uroplasty (2012–2014), which became Cogentix Medical after its 2015 merger with Vision-Sciences, where he then served as Lead Independent Director (2015–2016). He has also been listed as a director of Symmetry Surgical, Inc.

He holds an undergraduate degree from the University of Illinois (1977) and an MBA from Roosevelt University (1983).

• Operates within RoundTable Healthcare Partners' strategy: a healthcare-only private equity firm partnering with middle-market companies and using deep operating and transaction expertise to grow revenue and profitability.
• Sector targets (firm-level): medical products and devices, disposables, diagnostics, dental products, laboratory supplies, specialty distribution, contract manufacturing, generic and specialty pharmaceuticals, and consumer health (vitamins, probiotics, skincare, OTC, animal health).
• Scale (firm-level): RoundTable has raised roughly $4.25 billion across six equity funds ($3.65B) and three subordinated-debt funds ($600M); these are control/middle-market checks, not seed-stage angel checks.
• Stauner's personal value-add is operational: medical-device manufacturing, M&A, due diligence, and board-level governance rather than early-stage startup investing.